Thermo Fisher beats by $0.13, beats on revs; raises FY14 EPS & revenue guidance
Reports Q1 (Mar) earnings of $1.53 per share, $0.13 better than the Capital IQ Consensus Estimate of $1.40; revenues rose 22.3% year/year to $3.9 bln vs the $3.78 bln consensus.
- Co issues guidance for FY14, raises EPS to $6.80-6.95 from prior guidance of $6.70-6.90, excluding non-recurring items, vs. $6.85 Capital IQ Consensus Estimate; raises FY14 revs to $16.84-17.0 bln from prior guidance of $16.63-16.83 bln vs. $16.81 bln Capital IQ Consensus Estimate.
- "I'm pleased to report that the integration is on track, and we are confident that we will deliver on our previously outlined synergy targets. Our enhanced technology offering was already apparent when we showcased innovative new Thermo Scientific and Life Technologies products side by side at industry conferences. In Asia-Pacific and emerging markets, our combined scale is a key advantage in providing customers with solutions to achieve their goals."